Mankind Pharma Ltd (MANKIND)

Mankind Pharma Ltd Reports Strong Q3FY24 Results and Increased FII/FPI Holding - 29 Apr, 2024

Mankind Pharma Limited's revenue from operations grew by 21.84% in Q3FY24, accompanied by profits of Rs. 487 Crores. Additionally, FII/FPI increased their holding in the company from 6.74% to 9.87%. Positive outlook for Mankind Pharma.

Mankind Pharma Ltd stock up for fifth straight session - 26 Apr, 2024

Mankind Pharma Ltd's stock is up 0.33% on the day and has gained 69.19% in the last year, outperforming NIFTY and Nifty Pharma. The PE of the stock is 58.22 based on TTM earnings ending December 23.

ICICI Prudential Mutual Fund Acquires 1.6% Stake in Mankind Pharma - 17 Apr, 2024

ICICI Prudential Mutual Fund has acquired a 1.6% stake in Mankind Pharma Ltd. The company's Q3FY24 revenue increased by 21%, and net profit rose by 95%. The shares closed at Rs 2,295.00 per share, up 0.77% from the previous closing price.

Mankind Pharma Ltd Reports Strong Q3FY24 Results and Increased FII/FPI Holding - 14 Apr, 2024

Mankind Pharma Limited's revenue from operations grew by 21.84% in Q3FY24, accompanied by profits of Rs. 487 Crores. Additionally, FII/FPI increased their holding in the company from 6.74% to 9.87%. Positive outlook for Mankind Pharma.

Mankind Pharma Ltd Up 1.56% on NSE - 09 Apr, 2024

Mankind Pharma Ltd is up 1.56% on the NSE, trading at Rs 2395.3 as of 12:49 IST. The stock has gained 68.41% in the last year compared to a 28.76% gain in NIFTY and a 56% gain in the Nifty Pharma index. The PE ratio based on TTM earnings ending December 23 is 57.27.

Mankind Pharma Ltd's High P/E Ratio Raises Concerns for Investors - 08 Apr, 2024

Mankind Pharma Ltd has a high P/E ratio of 54.4x, indicating that investors are more bullish than analysts predict. While the company has strong earnings growth and is predicted to continue growing at a rate comparable to the market, potential risks exist for shareholders and investors.

Mankind Pharma to Sell OTC Business to Wholly-Owned Subsidiary - 04 Apr, 2024

Mankind Pharma has announced the slump sale of its Over the Counter (OTC) business to a wholly-owned subsidiary company. The move is part of Mankind's strategy to grow its OTC business with more focus.

Mankind Pharma Sells OTC Business, CEO Suggests Anti-Counterfeit Measures - 03 Apr, 2024

Mankind Pharma has announced the slump sale of its OTC business to a wholly-owned subsidiary. Meanwhile, the CEO suggests using hologram and blockchain technology to combat the sale of counterfeit drugs.

Mankind Pharma Approves Sale of OTC Business - 02 Apr, 2024

Mankind Pharma has approved the sale of its Over The Counter (OTC) business to a yet-to-be-incorporated wholly-owned subsidiary. The slump sale will enable the company to remain agile in the marketplace and build wider consumer reach.